MDGL News

Latest breaking news and updates for MDGL stock.

Track all markets on TradingView

Madrigal Receives European Commission Approval for Rezdiffraā„¢ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-...

How does Rezdiffra's market positioning compare to existing and pipeline MASH therapies in terms of competitive advantage and market share potential? What pricing and reimbursement strategy will Madrigal pursue in Europe, and how might that impact profit margins? How will the EU approval of Rezdiffra affect Madrigal's revenue forecasts and valuation?
Approval
4 days ago
Read more globenewswire

Madrigal Pharmaceuticals to Participate in theĀ Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Co...

How might the timing of the conference (August 12, 2025) intersect with upcoming SEC filing deadlines or other macroā€‘economic events that could impact the stock? What potential risks or downside catalysts might be highlighted during the presentation that traders should monitor? Could the conference provide insights into Madrigalā€™s competitive positioning within its therapeutic area relative to other pipelineā€‘heavy peers?
Events
12 days ago
Read more globenewswire